-PBR shares Amerigen Partners With Forest Laboratories For Generic Product Development explaining the collaboration will leverage Amerigen’s formulation expertise to develop a range of complex generic products and will commercialize resulting products in the US
– Building on the 480 million doses of the vaccine that GSK has already committed to GAVI through the Advance Market Commitment (AMC) framework, World Pharma News’ GSK Adds to its commitment to GAVI Alliance to Help Protect Millions More Children Against Infectious Diseases reveals GSK will provide an additional 240 million doses of Synflorix to developing countries over the next ten years, helping protect up to 80 million more children from pneumococcal diseases such as meningitis and pneumonia
– One of the effects of aging is reduced vision including presbyopia, the loss of the ability to see nearby objects. Johnson & Johnson Backs Company With Cornea Inlay to Improve Impaired Focus From Aging from MedCity News reports Johnson & Johnson Development Corp, the venture capital arm of J&J, is one of the latest backers for ReVision Optics, a company set on developing a procedure to improve reduced vision
– Sarepta Therapeutics announced that it plans to submit its muscular dystrophy drug, Eteplirsen, to the Food and Drug Administration in the first half of 2014. Innovative Muscular Dystrophy Drug Edges Closer To Market from Forbes points out that boys with muscular dystrophy tend to decline quickly and die in their early twenties. A drug that appears to reverse that is one that the FDA may well want to get on the market sooner rather than later
– Sanofi is on course to win US approval for the over-the-counter (OTC) use of its allergy drug Nasacort AQ. PMLive’s FDA Panel Backs OTC Use of Sanofi’s Allergy Drug explains if given final approval by the FDA, the nasal spray would be the first medicine of its kind available as on OTC product. The company will be hoping an OTC indication in the US will give it some advantage over the generic competition and boost sales, and is part of a wider plan to build its consumer healthcare business
